Chronic Kidney Disease
Part of NephTimes
Researchers studied the association between adolescent BMI and early CKD in young adulthood. Anemia associated with CKD can be treated with oral hypoxia-inducible factor prolyl hydroxylase inhibitors. Patients with diabetic kidney disease face increased risk of end-stage kidney disease and dialysis. Serum creatinine-based eGFR (eGFRcr) remains inaccurate and can overestimate eGFR, particularly in patients with sarcopenia. Strategies for the accurate evaluation of the risk of fragility fractures in elderly patients in the early stages of DKD. More negative values of the differences between eGFRcysC and eGFRScr were associated with poor health-related quality of life Patients with early chronic kidney disease (CKD) frequently develop anemia. The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%. Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes. Dr. Richard Lafayette discusses the FDA approval of TARPEYO, which reduces the loss of kidney function in IgA nephropathy. When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC. Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias. The primary efficacy end point of interest was the mean change in hemoglobin from baseline over weeks 12 to 16. Trials included in the analysis compared HIF-PHIs to placebo or to erythropoiesis-stimulating agents (ESA). Development and validation of a model to predict future trajectories in eGFR in adults with type 2 diabetes and CKD. A 2004 landmark study demonstrated an association between chronic kidney disease and an increased risk of CV events. Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes. There is an independent association between hyperkalemia and poor outcomes among individuals with chronic kidney disease. There are few data available on CKD-MBD among patients receiving peritoneal dialysis. Examining the potential benefits of pegloticase treatment in patients with CKD with refractory gout.